MedPath

Impact of Smoking, Benzodiazepine (BZD) Use and Obesity on Severe Obstructive Sleep Apnea (sOSA)

Completed
Conditions
Obesity
Smoking
Obstructive Sleep Apnea
Registration Number
NCT02539264
Lead Sponsor
Astes
Brief Summary

In this study the investigators will analyze the influence of smoking, benzodizepine use, and obesity among patients with severe Obstructive Sleep Apnea (sOSA).

Detailed Description

This study is a retrospective study. Patients enrolled: all patients with a PSG (polysomnography) between 1st January 2014 and 30th June 2015.

First analysis: influence of smoking, benzodiazepine use, and obesity on the AHI (Apnea Hypopnea Index: the number of apnea and hypopnea per hour of sleep).

Second analysis: only among patients with sOSA: influence of smoking, benzodiazepine use, and obesity on sleep fragmentation and night oximetry.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
920
Inclusion Criteria
  • All patients registered for an overnight PSG at Clinique Saint-Luc of Bouge
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Apnea Hypopnea Index1 day

Apnea Hypopnea Index (AHI) is defined as the number of apnea and hypopnea per hour of sleep. It is the major determinant of the severity of OSA.

Secondary Outcome Measures
NameTimeMethod
Sleep fragmentation defined by the percentage of time spent in each of the four stades of sleep (Stade 1, Stade 2, Slow wave sleep and Rapid Eye Movements)1 day

Are smoking and/or obesity a risk factor for sleep fragmentation?

Time spent under 90% of SpO2 during the night1 day

Are smoking and/or obesity a risk factor for oxygen desaturation (\< 90% SpO2) during the night?

© Copyright 2025. All Rights Reserved by MedPath